Mochi Health Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.6/10
Best for: coaching bundled into the price rather than sold separately
Mochi Health's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the plan
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
In the price
No insurance needed · Vetted by our editors
Mochi Health is an obesity medicine telehealth seller running aggressively priced compounded GLP-1 programs.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Mochi Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Mochi Health at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $139/mo (Membership $79/mo plus $60/mo for compounded semaglutide, read from joinmochi.com on 2026-08-14. Two qualifications t...)
- What's included
- Consult · Coaching
- Availability
- 15 states
- FDA status
- No FDA warning letter on record
How Mochi Health scores
Six columns, each one computed from something Mochi Health has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
4.4/10Publishes coverage in 15 of 50 states.
Support10%
4.0/10The price covers consult, coaching.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Mochi Health
Last checked July 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: 15 states
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Mochi Health involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Mochi Health publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Mochi Health does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering consult, coaching.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- Coverage is published for 15 of 50 states.
GLP-1 medications Mochi Health offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Membership $79/mo plus $60/mo for compounded semaglutide, read from joinmochi.com on 2026-08-14. Two qualifications the headline does not carry. The $39 membership figure the site leads with is first month only: its own footnote reads that the promotional rate applies to the first month for new customers and the standard rate is $79 per month afterwards. And $60 is a 'starting at' price marked 'price varies by dose', so it is the bottom of the ladder rather than a flat rate. $99 is shown struck through beside it.
Membership $79/mo plus $90/mo for compounded tirzepatide, read from joinmochi.com on 2026-08-14. Same two qualifications as the semaglutide row: $39 is a first-month promotional membership rate and the standard rate is $79, and $90 is a 'starting at' figure marked 'price varies by dose'. $199 is shown struck through beside it.
Check the price yourself before you pay
Every figure here was read off Mochi Health's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers consult and coaching
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Billed separately from the monthly figure: medication
- Coverage is published for 15 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Mochi Health charges
Mochi Health does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What Mochi Health dispenses
Mochi Health prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
What we could verify
On the record: it operates in 15 states and coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want coaching bundled rather than metered
Our read
We cannot tell you whether Mochi Health is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Mochi Health's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Mochi Health
Check today's price, then book the free consultation.
Where Mochi Health is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Mochi Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Mochi Health's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.